Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.
Blood. 2013 Apr 25;121(17):3431-3. doi: 10.1182/blood-2012-12-474569. Epub 2013 Feb 26.
Galectin-1 (Gal1) is a member of a highly conserved family of carbohydrate-binding proteins. It modulates innate and adaptive immune responses and fosters tumor-immune escape. Hodgkin lymphoma (HL) Reed-Sternberg cells overexpress and secrete Gal1, which selectively kills T helper (Th)1 and Th17 cells and cytotoxic T cells and promotes the immunosuppressive Th2/regulatory T-cell-predominant HL microenvironment. We developed a sandwich enzyme-linked immunosorbent assay and assessed serum Gal1 levels in 293 newly diagnosed, previously untreated patients with classical HL (cHL) enrolled in 3 risk-adapted clinical trials. Serum Gal1 levels were significantly higher in patients with cHL than in normal controls (P < .0001). Gal1 serum levels also increased with Ann Arbor stage (P = .012), areas of nodal involvement (P < .0001), and the International Prognostic Score (2-7, P = .019). We conclude that Gal1 serum levels are significantly associated with tumor burden and related clinical features in newly diagnosed cHL patients.
半乳糖凝集素-1（Gal1）是一种高度保守的糖结合蛋白家族成员。它调节先天和适应性免疫反应，并促进肿瘤免疫逃逸。霍奇金淋巴瘤（HL）的 Reed-Sternberg 细胞过度表达和分泌 Gal1，它选择性地杀死辅助性 T（Th）1 和 Th17 细胞以及细胞毒性 T 细胞，并促进免疫抑制性 Th2/调节性 T 细胞占主导地位的 HL 微环境。我们开发了一种夹心酶联免疫吸附试验，并评估了 293 名新诊断的、未经治疗的经典霍奇金淋巴瘤（cHL）患者的血清 Gal1 水平，这些患者入组了 3 项风险适应性临床试验。与正常对照组相比，cHL 患者的血清 Gal1 水平显著升高（P <.0001）。Gal1 血清水平也随着 Ann Arbor 分期（P =.012）、淋巴结受累区域（P <.0001）和国际预后评分（2-7，P =.019）的增加而升高。我们的结论是，Gal1 血清水平与新诊断的 cHL 患者的肿瘤负荷和相关临床特征显著相关。
